ADB-BUTINACA

ADB-BUTINACA is a compound that belongs to the cannabinoid class of chemicals. It is a synthetic cannabinoid receptor agonist (SCRA) that has been detected in products marketed as herbal smoking blends or research chemicals.

Chemistry

ADB-BUTINACA is a homolog of ADB-FUBINACA, which features a tert-butyl group replaced by a pentyl chain. The molecular formula of ADB-BUTINACA is C₂₁H₂₃N₃O₃. It is a white powder at room temperature.

Pharmacology

ADB-BUTINACA acts as a full agonist at the human cannabinoid receptor CB₁, with an EC₅₀ value of 0.78 nM. This makes it a potent compound with effects similar to those of cannabis, although the exact effects can vary depending on the dose and individual user's physiology.

Effects

The effects of ADB-BUTINACA can include relaxation, euphoria, altered perception, and in some cases, hallucinations. However, it can also cause adverse effects such as anxiety, paranoia, and in rare cases, seizures. Due to its potency and the lack of research on its long-term effects, it is considered a potentially dangerous substance.

Legal Status

ADB-BUTINACA is a controlled substance in many countries, including the United States, where it is classified as a Schedule I drug under the Controlled Substances Act. It is also controlled in many European countries under their respective drug laws.

See Also

• Synthetic cannabinoids
• Cannabinoid receptor
• Controlled Substances Act